駱卉妍主治醫(yī)師
中山大學(xué)附屬腫瘤醫(yī)院內(nèi)科
出生日期：1977年10月 工作單位：中山大學(xué)腫瘤防治中心內(nèi)科 通信地址：廣州市東風(fēng)東路651號 510060 E-mail: luohy@sysucc.org.cn 聯(lián)系電話：020-87342490 教育背景： 1995.09～2000.07 廣西醫(yī)科大學(xué)臨床醫(yī)學(xué)系醫(yī)學(xué)學(xué)士 2004.09～2007.06中山大學(xué)附屬腫瘤醫(yī)院腫瘤學(xué)碩士 2007.07～2010.07 中山大學(xué)附屬腫瘤醫(yī)院腫瘤學(xué)專科培訓(xùn)醫(yī)師 2012.09～2015.6中山大學(xué)腫瘤學(xué)和生物醫(yī)學(xué)工程聯(lián)合培養(yǎng)博士 2015.6～至今美國加州大學(xué)圣地亞哥分校訪問學(xué)者 工作經(jīng)歷： 2000.08～2004.08.作為住院醫(yī)師在桂林醫(yī)學(xué)院附屬醫(yī)院呼吸內(nèi)科工作 2004.09～2007.06中山大學(xué)附屬腫瘤醫(yī)院攻讀臨床型腫瘤學(xué)碩士研究生 2007.07～2010.07 中山大學(xué)附屬腫瘤醫(yī)院接受腫瘤學(xué)專科醫(yī)師培訓(xùn) 2010.-8至今作為主治醫(yī)師在中山大學(xué)附屬腫瘤醫(yī)院內(nèi)科工作 研究方向： 主要從事消化道腫瘤的化學(xué)治療和靶向治療，以及腫瘤耐藥和克服耐藥的基礎(chǔ)和轉(zhuǎn)化性研究。作為徐瑞華教授課題組主要研究人員參與國家自然科學(xué)基金項(xiàng)目、廣東省自然科學(xué)基金項(xiàng)目、廣州市科技計(jì)劃項(xiàng)目等多項(xiàng)科研課題，參與和完成多項(xiàng)I、II、III期臨床研究。在國內(nèi)外期刊發(fā)表文章50余篇，并以第一作者在Clin Cancer Res，J Cancer Res, Clin Oncol等雜志上發(fā)表SCI論文7篇。此外，還以第一作者發(fā)表綜述6篇，其中兩篇被2007年、2014年CSCO大會收錄。 承擔(dān)科研項(xiàng)目： 1)項(xiàng)目名稱：“新型聚氨酯納米材料載體克服奧沙利鉑耐藥的研究”，項(xiàng)目編號：(A2014251)，廣東省醫(yī)學(xué)科研基金項(xiàng)目，時間是2014年-2016年。項(xiàng)目負(fù)責(zé)人。 2)項(xiàng)目名稱：“Bmal1基因?qū)Y(jié)腸癌細(xì)胞生長的作用及機(jī)制研究”，項(xiàng)目編號：(81000888)，國家自然科學(xué)基金青年基金項(xiàng)目，時間是2011年-2014年。第三負(fù)責(zé)人。 3)項(xiàng)目名稱：“microRNA-214在結(jié)腸癌肝轉(zhuǎn)移中的作用及機(jī)制研究”，項(xiàng)目編號：(81372570)，國家自然科學(xué)基金面上項(xiàng)目，時間是2014年-2017年。第四負(fù)責(zé)人。 4) 項(xiàng)目名稱：“活性氧/NFkB 信號通路在腦膠質(zhì)瘤干細(xì)胞分化中的作用及其調(diào)控機(jī)制”,項(xiàng)目編號：(81302194)，國家自然科學(xué)基金青年基金項(xiàng)目，時間是2014年-2016年。第五負(fù)責(zé)人，負(fù)責(zé)數(shù)據(jù)的分析。 主要發(fā)表論文： 1. Zeng ZL, Luo HY(co-first author), Yang J, Wu WJ, Chen DL, Huang P, Xu RH*. Overexpression of the circadian clock gene Bmal1 increases sensitivity to oxaliplatin in colorectal cancer.Clin Cancer Res. Feb 15;20(4):1042-52, 2014. (SCI 8.77) 2. Luo HY, Xu RH.Predictive and prognostic biomarkers with therapeutic targets in advanced colorectal cancer.World J Gastroenterol. 2014 Apr 14;20(14):3858-74.(SCI 2.65) 3. Zhang Y, Luo HY(co-first author), Liu GL, Wang DS, Wang ZQ, Zeng ZL, Xu RH*. Prognostic significance and therapeutic implications of peroxisome proliferator-activated receptor overexpression in human pancreatic carcinoma.Int J Oncol. 2014 Oct 17. doi: 10.3892/ijo.2014.2709. (SCI 3.025) 4. Luo HY, Wang ZQ, Wang FH, Qiu MZ, Teng KY, Ruan DY, He YJ, Li YH, Xu RH*. Phase II study of capecitabine and irinotecan combination chemotherapy (modified XELIRI regimen) in patients with advanced gastric cancer. Am J Clin Oncol. Dec;34(6):555-60, 2011. (SCI 3.06) 5. Luo HY, Wei W, Shi YX, Chen XQ, Li YH, Wang F, Qiu MZ, Li FH, Yan SL, Zeng MS, Huang P, Xu RH*. Cetuximab enhances the effect of oxaliplatin on hypoxic gastric cancer cell lines. Oncol Rep. Jun;23(6):1735-45. 2010. (SCI 2.30) 6. Luo HY，Xu RH*, Wang F, Qiu MZ, Li YH, Li FH, Zhou ZW, Chen XQ. Phase II trial of XELOX as first-line treatment for patients with unresectable or metastatic gastric cancer. Chemotherapy. 56(2):94-100. 2010 (SCI 1.28) 7. Li YH, Luo HY(co-first author)，Wang FH, Wang ZQ, Qiu MZ, Shi YX, Xiang XJ, Chen XQ, He YJ, Xu RH*. Phase II study of capecitabine plus oxaliplatin (XELOX) as first-line treatment and followed by maintenance of capecitabine in patients with metastatic colorectal cancer. J Cancer Res Clin Oncol.Apr;136(4):503-10. 2010 (SCI 3.09) 8. Chen DL, Wang ZQ, Zeng ZL, Wu WJ, Zhang DS, Luo HY, Wang F, Qiu MZ, Wang DS, Ren C, Wang FH, Chiao LJ, Pelicano H, Huang P, Li YH, Xu RH. Identification of microRNA-214 as a negative regulator of colorectal cancer liver metastasis by way of regulation of fibroblast growth factor receptor 1 expression.Hepatology. 2014 Aug;60(2):598-609. (SCI 11.19) 9. Chen DL, Wang DS, Wu WJ, Zeng ZL, Luo HY, Qiu MZ, Ren C, Zhang DS, Wang ZQ, Wang FH, Li YH, Kang TB, Xu RH. Overexpression of paxillin induced by miR-137 suppression promotes tumor progression and metastasis in colorectal cancer.Carcinogenesis. 2013 Apr;34(4):803-11. (SCI 5.26) 10. An X, Wang F, Shao Q, Wang FH, Wang ZQ, Wang ZQ, Chen C, Li C, Luo HY, Zhang DS, Xu RH, Li YH. MET amplification is not rare and predicts unfavorable clinical outcomes in patients with recurrent/metastatic gastric cancer after chemotherapy.Cancer. 2014 Mar 1;120(5):675-82. Epub 2013 Nov 5. 11. Chen WW, Wang F, Zhang DS, Luo HY, Wang ZQ, Wang FH, Qiu MZ, Ren C, Wei XL, Wu WJ, Li YH, Xu RH. Primary small cell carcinoma of the esophagus: clinicopathological study of 44 cases.BMC Cancer. 2014 Mar 25;14:222. doi: 10.1186/1471-2407-14-222 12. Wang DS, Luo HY, Qiu MZ, Wang ZQ, Zhang DS, Wang FH, Li YH, Xu RH*. Comparison of the prognostic values of various inflammation based factors in patients with pancreatic cancer.Med Oncol. Dec;29(5):3092-100.2012 (SCI 2.14) 13. Dai SQ, An X, Wang F, Shao Q, Chen YC, Kong YN, Chen C, Li C, Luo HY, Liang Y, Wang FH, Xu RH, Li YH*. Serum HER 2 extracellular domain level is correlated with tissue HER 2 status in metastatic gastric or gastro-oesophageal junction adenocarcinoma.PLoS One. May 14;8(5):e63458.2013 (SCI 3.73) 14. Qiu MZ, Wang ZQ, Zhang DS, Liu Q, Luo HY, Zhou ZW, Li YH, Jiang WQ, Xu RH *. Comparison of 6th and 7th AJCC TNM staging classification for carcinoma of the stomach in China.Ann Surg Oncol. Jul;18(7):1869-76. 2011 (SCI 4.18) 15. Ren C, Qiu MZ, Wang DS, Luo HY, Zhang DS, Wang ZQ, Wang FH, Li YH, Zhou ZW, Xu RH*. Prognostic effects of 25-hydroxyvitamin D levels in gastric cancer. J Transl Med. Jan 27;10:16, 2012 . (SCI 3.45) 16. Chen DL, Wang ZQ, Ren C, Zeng ZL, Wang DS, Luo HY, Wang F, Qiu MZ, Bai L, Zhang DS, Wang FH, Li YH, Xu RH*. Abnormal expression of paxillin correlates with tumor progression and poor survival in patients with gastric cancer.J Transl Med. Nov 2;11:277. 2013 (SCI 3.45) 17. He MM, Zhang DS, Wang F, Wang ZQ, Luo HY, Jin Y, Wei XL, Xu RH*. The role of non-curative surgery in incurable, asymptomatic advanced gastric cancer.PLoS One. Dec 16;8(12):e83921. 2013 (SCI 3.73) 18. He MM, Zhang DS, Wang F, Wang ZQ, Luo HY, Ren C, Jin Y, Chen DL, Xu RH*. Adjuvant chemotherapy, p53, carcinoembryonic antigen expression and prognosis after D2 gastrectomy for gastric adenocarcinoma.World J Gastroenterol. Jan 7;20(1):264-73.2014 (SCI 2.55) 19. Li ZH, Qiu MZ, Zeng ZL, Luo HY, Wu WJ, Wang F, Wang ZQ, Zhang DS, Li YH, Xu RH*. Copper-transporting P-type adenosine triphosphatase (ATP7A) is associated with platinum-resistance in non-small cell lung cancer (NSCLC). J Transl Med. 2012 Feb 3;10(1):21. 20. Wang DS, Ren C, Qiu MZ, Luo HY, Wang ZQ, Zhang DS, Wang FH, Li YH, Xu RH*. Comparison of the prognostic value of various preoperative inflammation-based factors in patients with stage III gastric cancer.Tumour Biol. 2011 Dec 24 21. Qiu HB, Chen G, Keshari RP, Luo HY, Fang W, Qiu MZ, Zhou ZW, Xu RH*. The extramural metastasis might be categorized in lymph node staging for colorectal cancer. BMC Cancer. 2011 Sep 26;11(1):414. 22. Wang DS, Zhang DS, Qiu MZ, Wang ZQ, Luo HY, Wang FH, Li YH, Xu RH*. Prognostic factors and survival in patients with neuroendocrine tumors of the pancreas. Tumour Biol. 2011 Aug;32(4):697-705. 23. Wang DS, Chen DL, Ren C, Wang ZQ, Qiu MZ, Luo HY, Zhang DS, Wang FH, Li YH, Xu RH*. ABO blood group, hepatitis B viral infection, and risk of pancreatic cancer. Int J Cancer. 2011 Aug 19. doi: 10.1002/ijc.26376. 24. Qiu MZ, Wang ZQ, Zhang DS, Liu Q, Luo HY, Zhou ZW, Li YH, Jiang WQ, Xu RH*. Prognostic analysis in node-negative gastric cancer patients in China. Tumour Biol. 2011 Jul;18(7):1869-76. Epub 2011 Jan 19. 25. Qiu MZ, Wang ZQ, Luo HY, Zhang DS, Zhou ZW, Li YH, Jiang WQ, Xu RH*. Clinicopathological characteristics and prognostic analysis of gastric cancer in the young adult in China. Tumour Biol. 2011 Jun;32(3):509-14. 26. Qiu HB, Zhang LY, Zeng ZL, Wang ZQ, Luo HY, Keshari RP, Zhou ZW, Xu RH*. HBV infection decreases risk of liver metastasis in patients with colorectal cancer: A cohort study. World J Gastroenterol. 2011 Feb 14;17(6):804-8. 27. Teng KY, Qiu MZ, Li ZH, Luo HY, Zeng ZL, Luo RZ, Zhang HZ, Wang ZQ, Li YH, Xu RH*. DNA polymeraseeta protein expression predicts treatment response and survival of metastatic gastric adenocarcinoma patients treated with oxaliplatin-based chemotherapy. J Transl Med. 2010 Nov 27;8(1):126 28. Li FH, Shen L, Li ZH, Luo HY, Qiu MZ, Zhang HZ, Li YH, Xu RH*. Impact of KRAS mutation and PTEN expression cetuximab-treated colorectal cancer. W J of Gastroenterology 2010 Dec 14:16(46):5881-5888. 29. Qiu MZ, Xu RH*, Ruan DY, Li ZH, Luo HY, Teng KY, Wang ZQ, Li YH, Jiang WQ. Ruan DY et al. Incidence of anemia, leukocytosis, and thrombocytosis in patients with solid tumors in China. Tumour Biol.2010 Dec;31(6):633-41. 30. Qiu MZ, Yuan ZY, Luo HY, Ruan DY, Wang ZQ, Wang FH, Li YH, Xu RH*. Impact of pretreatment hematologic profile on survival of colorectal cancer patients. Tumour Biol. 2010 Aug;31(4):255-60
腫瘤內(nèi)科治療的臨床工作及轉(zhuǎn)化研究?
